Cannabis and Performance Anxiety
What the evidence actually says about using cannabis for stage fright, public speaking, and high-pressure situations.
Performance anxiety is one of the worst use cases for cannabis, and one of the most common. Low doses of CBD have modest evidence for situational anxiety. THC is bimodal: a little might calm you, a little more reliably makes anxiety worse, and the line between the two is narrow and unpredictable in social or evaluative settings. If you need to perform, beta-blockers and rehearsal beat weed almost every time. Most claims you'll see online are folklore, not data.
Not medical advice
This article is not medical advice. It summarizes published evidence as of its writing. Anxiety disorders are treatable, and the standard treatments work well for most people. If performance anxiety is interfering with your work or life, talk to a licensed clinician — ideally one who is neutral about cannabis rather than for or against it. Drug interactions, pregnancy, cardiovascular conditions, and psychiatric history all matter and are beyond the scope of an encyclopedia article.
Plain-language summary
Performance anxiety — the spike of fear before a speech, audition, exam, or athletic event — is a normal stress response that becomes a problem when it impairs the thing you're trying to do. People reach for cannabis because it feels relaxing in casual settings. But evaluative situations are different: you are being watched, judged, and your body is already in a sympathetic-nervous-system surge.
The research on cannabis in this specific situation is thin. The clearest signal comes from a small set of studies using isolated CBD (not whole-plant cannabis) before a simulated public-speaking test, where high single doses reduced anxiety in people with social anxiety disorder Weak / limited [1][2]. THC is more complicated: at low doses it can blunt anxiety, at higher doses it reliably causes anxiety, including in healthy users Strong evidence [3]. Inhaled cannabis as people actually use it has not been tested for performance anxiety in controlled trials No data.
What probably works (relatively speaking)
Single-dose oral CBD, 300–600 mg, taken 60–90 minutes before the event. Two small controlled studies in people with social anxiety disorder found reduced subjective anxiety during a simulated public-speaking test at 300 mg [1] and at 600 mg [2]. A separate study in healthy volunteers showed CBD reduced anxiety in a similar paradigm Weak / limited [4].
Caveats that matter:
- Sample sizes were small (under 60 participants combined across these key trials).
- Doses were of pharmaceutical-grade isolated CBD, not gummies of uncertain content. Independent testing has repeatedly found CBD products mislabeled Strong evidence [5].
- The dose-response curve appears inverted-U: 300 mg helped, 150 mg and 900 mg did not in one study [2].
- Effects were on subjective anxiety, not necessarily on observable performance.
This is the best-supported cannabis-related option, and it's still weak evidence by the standards of clinical medicine.
What might work (use caution)
Very low-dose THC — in the range of 5–7.5 mg oral, or a single small inhalation of a low-THC product — has shown anxiety reduction in some lab studies of stress response Weak / limited [6]. The problem: in the same study, 12.5 mg increased anxiety and worsened mood. The therapeutic window is narrow, individual variation is large, and tolerance shifts it further.
Full-spectrum / high-CBD low-THC products are often marketed for anxiety. Mechanistically plausible, but there are no controlled performance-anxiety trials of these products specifically No data. The 'entourage effect' is a real hypothesis but not a proven clinical phenomenon at this level of specificity — treat marketing claims about specific terpene ratios for anxiety as folklore Anecdote.
What doesn't work or has weak/negative evidence
- Smoking or vaping high-THC flower before a performance. No controlled evidence supports this, and acute THC intoxication impairs working memory, reaction time, and verbal recall Strong evidence [7] — exactly the faculties most performances require.
- 'Indica for anxiety.' The indica/sativa distinction does not reliably predict chemical content or effects Strong evidence [8]. This is folklore.
- Picking a strain by terpene profile (e.g. 'high myrcene' or 'high linalool') to treat anxiety. Mechanistic studies in animals exist, but no controlled human trials show that consumer-level terpene differences in cannabis flower produce clinically meaningful anxiolytic effects No data.
- Daily heavy cannabis use to manage chronic performance anxiety. Observational data link heavy use to higher rates of anxiety disorders, though causality is debated Disputed [9].
What we don't know
- Whether inhaled cannabis at carefully titrated low THC doses could match oral CBD for situational anxiety. No trials.
- Optimal CBD dose, timing, and formulation for performance anxiety specifically (vs. generalized or social anxiety).
- Whether CBD's effect generalizes from lab public-speaking tasks to real auditions, exams, or athletic competition.
- Long-term effects of repeated pre-performance cannabis use on baseline anxiety, tolerance, and performance quality.
- Interactions with beta-blockers, SSRIs, and benzodiazepines in real-world combined use.
Comparison with standard treatments
For acute, situational performance anxiety (a specific event):
- Beta-blockers (propranolol 10–40 mg, ~1 hour before) have decades of use among musicians, public speakers, and surgeons. They blunt the physical symptoms — tremor, racing heart, sweating — without sedation or cognitive impairment Strong evidence [10]. This is the most-used off-label drug for stage fright among professionals.
- Behavioral preparation: rehearsal, exposure, paced breathing, and cognitive reframing have strong evidence and no pharmacologic risk Strong evidence.
For chronic social anxiety disorder:
- Cognitive-behavioral therapy is first-line and has the most durable effects Strong evidence [11].
- SSRIs and SNRIs are well-established pharmacotherapy Strong evidence [11].
No cannabis product currently has regulatory approval for any anxiety disorder. CBD-based Epidiolex is approved for specific epilepsies, not anxiety.
Risks and practical considerations
- THC can trigger acute anxiety, panic, and (rarely) transient psychotic symptoms, especially at higher doses, in inexperienced users, or in those with psychiatric vulnerability Strong evidence [3][7].
- Cognitive impairment. Even 'mild' acute intoxication impairs the very skills most performances test Strong evidence [7].
- Cardiovascular effects. THC raises heart rate; relevant if you already have palpitations from anxiety or known cardiac disease Strong evidence [12].
- Product reliability. CBD products are frequently mislabeled, and gas-station 'CBD' may contain THC, synthetic cannabinoids, or contaminants Strong evidence [5].
- Drug testing. Even pure CBD products may contain trace THC sufficient to fail workplace tests over time.
- Dependence and tolerance with regular use can convert an occasional aid into a daily requirement, raising baseline anxiety on non-use days.
If you're going to experiment, do it on a low-stakes day first — never test a new dose for the first time on the day of the performance.
Sources
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226.
- Peer-reviewed Zuardi AW, Rodrigues NP, Silva AL, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Frontiers in Pharmacology. 2017;8:259.
- Peer-reviewed Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Human Psychopharmacology. 2009;24(7):515-523.
- Peer-reviewed Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry. 2019;41(1):9-14.
- Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708-1709.
- Peer-reviewed Childs E, Lutz JA, de Wit H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug and Alcohol Dependence. 2017;177:136-144.
- Peer-reviewed Crean RD, Crane NA, Mason BJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. Journal of Addiction Medicine. 2011;5(1):1-8.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. 2022;17(5):e0267498.
- Peer-reviewed Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population—a meta-analysis of 31 studies. BMC Psychiatry. 2014;14:136.
- Peer-reviewed Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology. 2016;30(2):128-139.
- Government National Institute for Health and Care Excellence (NICE). Social anxiety disorder: recognition, assessment and treatment. Clinical guideline CG159. 2013. ↗
- Peer-reviewed Sidney S. Cardiovascular consequences of marijuana use. Journal of Clinical Pharmacology. 2002;42(S1):64S-70S.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Social Anxiety Disorder — What the evidence actually says about using cannabis, CBD, and THC for social anxiety — an...